Clinical trials: Influenza Vaccines
Influenza
H5N1 Vaccine Study in Japanese Elderly Population Aged 65 Years and Older
The purpose of this study is to obtain immunogenicity and safety data of an H5N1 pandemic influenza vaccine in a Japanese elderly population aged 65 years and older.
- Trial name
- NCT01774032
- Testing
- H5N1 Influenza Vaccine (Whole Virion, Vero Cell-Derived, Inactivated), non-adjuvanted formulation
- Where
- 2 sites in Japan
- Volunteers
- 91 people, healthy volunteers welcome
- Sponsor
- Alachua Government Services, Inc.
SARS-CoV-2 Infection, Influenza A
Clinical Validation of an At-Home Flu A/B and COVID-19 Rapid Test
The study's primary objective is to evaluate the performance of the CorDx Tyfast Flu A/B \& COVID-19 At-Home Test for detecting SARS-CoV-2, Influenza A, and B in nasal samples collected by lay users, compared to 510(k)-cleared…
- Conditions
- SARS-CoV-2 Infection, Influenza A, Influenza B
- Trial name
- NCT07430410
- Testing
- CorDx Tyfast Flu A/B & COVID-19 At-Home Multiplex Rapid Test
- Volunteers
- 200 people
- Sponsor
- CorDx, Inc.
H7N9 Influenza
A Study of An Adjuvanted Inactivated H7N9 Influenza Vaccine
The aim of this study is to investigate the immunogenicity and safety of the inactivated whole-virion vaccine for teenagers and adults.
- Trial name
- NCT03755427
- Testing
- 15μg H7N9 Vaccine, Aluminum Hydroxide Adjuvant
- Where
- China
- Volunteers
- 560 people, healthy volunteers welcome
- Sponsor
- Shanghai Institute Of Biological Products
Haemophilus Influenzae, Streptococcus Pneumoniae
Study to Assess the Safety of a New GSK Biologicals' GSK2231395A Candidate Vaccine
The purpose of this study is to evaluate the safety, reactogenicity and immunogenicity of GSK2231395A candidate vaccine in adults and elderly adults with chronic obstructive pulmonary disease.
- Trial name
- NCT00849069
- Testing
- GSK2231395A, TwinrixTM
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- GlaxoSmithKline
Enhancement of Protective Antibody Response After Probiotic Consumption
Effect of a Mixture of Probiotics on the Antigen Specific Antibody Response in a Influenza Vaccination Model of Healthy Adults
the aim of the study is to get evidence for an enhancement of immune status in subjects after probiotics mixture consumption ( lactobacillus gasseri PA 16/8, Bifidobacterrium longum SP 07/3, Bifidobacterium bifidum MF 20/5) based…
- Trial name
- PROBIMMUNE (NCT01652066)
- Testing
- Mixture of probiotics, Mixture of probitiocs
- Where
- France
- Volunteers
- 430 people, healthy volunteers welcome
- Sponsor
- Merck Medication Familiale
Influenza
A Study to Evaluate the Safety of 3 New 6:2 Influenza Virus Reassortants in Adults
This prospective annual release study was designed to assess the safety of a trivalent influenza virus vaccine using two new strains recommended for the 2012-2013 influenza season not previously contained in the trivalent…
- Trial name
- NCT01579916
- Testing
- Trivalent Influenza Virus Vaccine
- Where
- 3 sites in United States
- Volunteers
- 303 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Influenza
Study of the Immunogenicity and Safety of a Quadrivalent Influenza Vaccine (VAX2012Q) in Adults 18-64 Years
This is a multi-center, randomized, double-blind, active comparator controlled study in which up to 450 healthy adults age 18-64 years will be administered either one of two dose levels of VAX2012Q or a licensed quadrivalent…
- Trial name
- NCT02434276
- Testing
- VAX2012Q, Fluzone Quadrivalent
- Where
- 6 sites in United States
- Volunteers
- 450 people, healthy volunteers welcome
- Sponsor
- VaxInnate Corporation
SARS-CoV-2, Influenza
A Study of mRNA-based Influenza and SARS-CoV-2 (COVID-19) Multi-component Vaccines in Healthy Adults
The study is divided into 2 parts: Part 1 and Part 2. The purpose of Part 1 of this study is to generate sufficient safety, reactogenicity, and immunogenicity data to enable selection of an mRNA-1083 vaccine composition and dose…
- Trial name
- NCT05827926
- Testing
- Influenza Vaccine 1, mRNA-1083.1, mRNA-1083.2
- Where
- 69 sites in United States
- Volunteers
- 1,758 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Influenza, Common Cold
A Comparison of Solid and Soluble Forms of Cold and Influenza Remedies
The study is designed to investigate whether paracetamol from a hot remedy reaches the plasma faster than standard paracetamol tablets.
- Trial name
- NCT01332578
- Testing
- Paracetamol, Phenylephrine, Ascorbic Acid
- Where
- United Kingdom
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Evaluate Safety & Immunogenicity of a Pandemic Influenza Vaccine (GSK1562902A) in Children
The present study is designed to evaluate in children (aged between 3 and 9 years) the immunogenicity and safety of different antigen doses of the candidate vaccine (GSK1562902A) administered following a two-administration…
- Trial name
- NCT00502593
- Testing
- Pandemic Influenza Vaccine (GSK1562902A), Fluarix™
- Where
- 7 sites in Spain
- Volunteers
- 138 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Healthy
Safety and Efficacy Study of Inhaled PUR003 on a Controlled Influenza Virus Challenge in Healthy Adult Subjects
The objectives of the study are to demonstrate the effectiveness, safety and tolerability of multiple daily doses of inhaled PUR003, in comparison with placebo, in healthy adults experimentally inoculated with Influenza…
- Trial name
- NCT00947687
- Testing
- PUR003
- Where
- United Kingdom
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Pulmatrix Inc.
Herpes Zoster
A Study of an Investigational Zoster Vaccine in Subjects With a History of Varicella (Chickenpox) Given Concomitantly With Another Vaccine (V211-011)
The purpose of this study is to determine whether the investigational zoster vaccine has a comparable immune response (the body's ability to protect against disease) and safety profile when given concomitantly with another…
- Trial name
- NCT00231816
- Testing
- ZOSTAVAX™ (concomitant), Comparator: Influenza Vaccine, ZOSTAVAX™ (Nonconcomitant)
- Volunteers
- 763 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Influenza
Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline Biologicals' Influenza Vaccine in Elderly People
The purpose of the study is to evaluate the safety of GSK Biologicals' influenza vaccine. Elderly subjects were randomized in the primary study (NCT00760617) and will now receive the same vaccine for the third time.
- Trial name
- NCT00992784
- Testing
- GSK investigational vaccine 2186877A, FluarixTM
- Where
- 24 sites in Germany, Netherlands and 1 more
- Volunteers
- 370 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Evaluate Safety & Immunogenicity of a Pandemic Influenza Vaccine (GSK1562902A) in Adults Over 60 Years of Age
The present study is designed to evaluate the immunogenicity and safety of a single or double dose of the pandemic influenza candidate vaccine (GSK1562902A), administered following a two-administration schedule (21 days apart) in…
- Trial name
- NCT00397215
- Testing
- Pandemic influenza vaccine (GSK1562902A) (adjuvanted or not), Fluarix
- Where
- 12 sites in Belgium, Italy
- Volunteers
- 437 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Prophylaxis of Avian Influenza Vaccine
Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Adults Unprimed and Primed With Adjuvanted or Non-adjuvanted Influenza Vaccines
Valuate the immune response and reactogenicity of H5N1 vaccination in a primed population (H5N3 adjuvanted or non-adjuvanted vaccine) compared to immunologically naïve subjects
- Trial name
- NCT00478816
- Testing
- Fluad H5N1 Pandemic Influenza Vaccine
- Where
- United Kingdom
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Influenza
Study to Evaluate Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine GSK2282512A When Administered to Children 6 to 35 Months of Age
The purpose of this study is to investigate the immunogenicity, reactogenicity and safety of the new influenza vaccine GSK2282512A (FLU-Q-QIV) and compare its activity to the marketed vaccine Fluarix® (TIV) in young children 6 to…
- Trial name
- NCT01711736
- Testing
- Quadrivalent influenza GSK2282512A vaccine, Fluarix
- Where
- 8 sites in Canada, Dominican Republic and 1 more
- Volunteers
- 606 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Orthomyxoviridae Infections, Influenza
Immunogenicity Study of the Influenza Vaccine in Adults
All marketed influenza vaccines are injected by the intramuscular (IM) route. This study will test whether an influenza vaccine is effective when injected by a route other than into the muscle.
- Trial name
- NCT00258934
- Testing
- Inactivated, split-virion influenza vaccine, Inactivated, split-virion, influenza virus
- Where
- 4 sites in Belgium, Germany and 1 more
- Volunteers
- 978 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza
A Prospective Epidemiological Study Evaluating Occurrences of Influenza-like Illness
This prospective epidemiological cohort study is being conducted in order to generate epidemiological data in support of Osivax's clinical development of a broad-spectrum influenza vaccine based upon the internal influenza…
- Trial name
- NCT06779981
- Testing
- Nasopharyngeal swabs
- Where
- Belgium
- Volunteers
- 119 people, healthy volunteers welcome
- Sponsor
- Osivax
Influenza
A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1010 in Healthy Adults
The main purpose of the study is to evaluate the safety, reactogenicity, and the humoral immunogenicity of mRNA-1010 and comparator influenza vaccines against homologous influenza A and B strains at Day 29.
- Trial name
- NCT05606965
- Testing
- mRNA-1010, Egg-based Quadrivalent Influenza Vaccine, Adjuvanted Quadrivalent Influenza Vaccine
- Where
- United States
- Volunteers
- 172 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Seasonal Influenza
Safety and Immunogenicity of an A (H1N1) 2009 Influenza Virus-like Particle (VLP) Vaccine
This is a Phase 2 randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability and immunogenicity of three dose levels (5µg, 15µg and 45µg HA) of the novel A (H1N1) influenza VLP vaccine as compared…
- Trial name
- NCT01072799
- Testing
- A/H1N1 2009 Influenza VLP Vaccine
- Where
- Mexico
- Volunteers
- 4,560 people, healthy volunteers welcome
- Sponsor
- Novavax
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.